Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Otolaryngology Residency
74%
Research Productivity
74%
Academic Achievement
74%
Residency
74%
First Author
56%
Otolaryngology Residency Programs
41%
Fellowship Training
41%
Review Authors
37%
Proximal Humerus Fracture
37%
Financial Conflicts of Interest
37%
Antipsychotics
37%
Statin Therapy
37%
Dyslipidemia
37%
Effect Estimates
37%
Pooling Effect
37%
PubMed
36%
Risk of Bias
34%
Financial Bias
29%
Total Publications
26%
Academic Medicine
26%
Severe Mental Illness
25%
Statins
25%
Blood Pressure
25%
Second-generation Antipsychotics
25%
Safety Concerns
25%
RoB2
24%
Lowering Blood Lipid
24%
Academic Career
24%
Embase
19%
Commercial Sites
18%
Coronary Artery Bypass Surgery
18%
Publication Rate
16%
Google Scholar
16%
Scopus
16%
Hirsch Index
16%
Sectional Analysis
16%
Academic Success
16%
Small Sample Size
14%
Meta-analysis
12%
Lipids
12%
Lipid Levels
12%
Lipid Profile
12%
ROBINS-I
12%
Grading Criteria
12%
Lipid-lowering Therapy
12%
Article Type
12%
Cardiovascular Risk Factors
12%
LDL-C Level
12%
Change in BMI
12%
Adverse Effects
12%
Social Sciences
Authors
100%
Academic Achievement
74%
Residency Programs
59%
Source credibility
37%
Public Perception
37%
Older Adults
37%
Multiple Sclerosis
37%
Diseases
37%
USA
37%
Conflict of Interest
37%
Variance
37%
Medical Science
36%
Academic Career
27%
Occupational Career
19%
Academic Success
19%
Random Sample
19%
Online News
9%
Misinformation
9%
Graduate Medical Education
7%
Research Process
7%
Medical Training
7%
Education
7%
Familiarity
7%
Administrative Structure
7%
Accreditation
7%
Medical Student
7%
Pharmacology, Toxicology and Pharmaceutical Science
Statin (Protein)
74%
Lipid
74%
Dyslipidemia
56%
Mental Diseases
46%
Heart Arrest
37%
Drug Development
37%
Malignant Neoplasm
37%
Afatinib
37%
Naloxone
37%
Clinical Trial
37%
Multiple Sclerosis
37%
Antipsychotic
37%
Adverse Event
20%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
18%
Non Small Cell Lung Cancer
10%
Diseases
10%
Heart Infarction
9%
Cardiovascular Risk
9%
Side Effect
9%
Cardiovascular Disease
9%
Monotherapy
5%
Squamous Cell Carcinoma
5%
Breast Cancer
5%
Off-Label Use
5%